Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
89bio, Inc. ETNB
$17.52
-$0.07 (-0.40%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1314533236.00000000
-
week52high
18.11
-
week52low
2.12
-
Revenue
0
-
P/E TTM
-8
-
Beta
0.76834600
-
EPS
-2.90000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 июл 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 30 июн 2022 г. |
| Oppenheimer | Outperform | Outperform | 30 июн 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 14 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Le-Nguyen Quoc | D | 64709 | 695 | 01 февр 2023 г. |
| Mansbach Harry H | D | 68158 | 680 | 01 февр 2023 г. |
| Martins Ryan | D | 35960 | 408 | 01 февр 2023 г. |
| Martins Ryan | D | 36368 | 5947 | 03 янв 2023 г. |
| Mansbach Harry H | D | 68838 | 3113 | 15 ноя 2022 г. |
| Mansbach Harry H | A | 71951 | 9000 | 15 ноя 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 8955410 | 1172741 | 18 окт 2022 г. |
| Le-Nguyen Quoc | D | 65404 | 1297 | 30 сент 2022 г. |
| Le-Nguyen Quoc | A | 66701 | 3750 | 30 сент 2022 г. |
| Martins Ryan | D | 42315 | 2018 | 28 сент 2022 г. |
Новостная лента
Orbimed Advisors Reduces Position in 89bio
24/7 Wall Street
27 янв 2023 г. в 22:27
Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of 89bio Inc (ETNB).
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks Investment Research
17 янв 2023 г. в 13:33
89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
89Bio: Let's Not Give Up Already
Seeking Alpha
22 дек 2022 г. в 08:34
ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action.
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
GlobeNewsWire
13 окт 2022 г. в 08:00
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17, 2022 at 11:30 AM ET.
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 08:00
SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET.